Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Lease Agreements (Tables)

6 Months Ended

Jun. 30, 2019

For the three and six months ended June 30, 2019, the components of our operating lease expense were as follows (in thousands):


		Three Months Ended		Six Months Ended
		June 30,		June 30,
	2019		2019
Fixed operating lease expense	$	1,312	$	2,568
Variable operating lease expense		129		378
Total operating lease expense	$	1,441	$	2,946

Supplemental information related to the Company’s operating lease for the three and six months ended June 30, 2019 were as follow (in thousands):


Cash payments included in the measurement of operating lease liabilities	$	2,338	$	4,646
Right-of-use asset obtained in exchange for operating lease obligations		—		—

The following table presents the future lease payments of our operating lease liabilities as of June 30, 2019 (in thousands):


Remainder of 2019	$	4,676
2020		9,694
2021		10,082
2022		10,485
2023		877
Total operating lease payments		35,814
Less: imputed interest		(5,726)
Total operating lease liabilities	$	30,088

For the three and six months ended June 30, 2019, we have the following operating sublease information (in thousands):

The following table presents the future lease payments we expect to receive under our sublease as of June 30, 2019 (in thousands):


Remainder of 2019	$	2,103
2020		4,360
2021		4,534
2022		4,716
2023		394
Total operating lease liabilities	$	16,107